EA013544B1 - Применение оксикодона для лечения висцеральной боли - Google Patents

Применение оксикодона для лечения висцеральной боли Download PDF

Info

Publication number
EA013544B1
EA013544B1 EA200701541A EA200701541A EA013544B1 EA 013544 B1 EA013544 B1 EA 013544B1 EA 200701541 A EA200701541 A EA 200701541A EA 200701541 A EA200701541 A EA 200701541A EA 013544 B1 EA013544 B1 EA 013544B1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxycodone
salt
dosage form
pain
morphine
Prior art date
Application number
EA200701541A
Other languages
English (en)
Russian (ru)
Other versions
EA200701541A1 (ru
Inventor
Асбьёрн Мор Древес
Ларс Аренд Нильсен
Original Assignee
Еуро-Селтик С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA013544(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Еуро-Селтик С.А. filed Critical Еуро-Селтик С.А.
Publication of EA200701541A1 publication Critical patent/EA200701541A1/ru
Publication of EA013544B1 publication Critical patent/EA013544B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
EA200701541A 2005-01-18 2006-01-17 Применение оксикодона для лечения висцеральной боли EA013544B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Publications (2)

Publication Number Publication Date
EA200701541A1 EA200701541A1 (ru) 2008-02-28
EA013544B1 true EA013544B1 (ru) 2010-06-30

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701541A EA013544B1 (ru) 2005-01-18 2006-01-17 Применение оксикодона для лечения висцеральной боли

Country Status (31)

Country Link
US (2) US20080200493A1 (https=)
EP (1) EP1838318B1 (https=)
JP (1) JP5049139B2 (https=)
KR (10) KR20070100368A (https=)
CN (1) CN101106996B (https=)
AP (1) AP2249A (https=)
AR (1) AR052880A1 (https=)
AT (2) ATE446092T1 (https=)
AU (1) AU2006207498B2 (https=)
BR (1) BRPI0606247A2 (https=)
CA (1) CA2595043C (https=)
CY (1) CY1109660T1 (https=)
DE (2) DE202006019887U1 (https=)
DK (2) DK1838318T3 (https=)
EA (1) EA013544B1 (https=)
ES (1) ES2333901T3 (https=)
HR (1) HRP20090679T1 (https=)
IL (1) IL184530A (https=)
ME (1) ME01066B (https=)
MX (1) MX2007007207A (https=)
MY (1) MY144471A (https=)
NO (1) NO338968B1 (https=)
NZ (1) NZ555852A (https=)
PL (1) PL1838318T3 (https=)
PT (1) PT1838318E (https=)
RS (1) RS51069B (https=)
SI (1) SI1838318T1 (https=)
TW (1) TWI432196B (https=)
UA (1) UA85471C2 (https=)
WO (1) WO2006077212A1 (https=)
ZA (1) ZA200705231B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY153249A (en) 2005-11-14 2015-01-29 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
CA2716424C (en) 2008-03-04 2015-04-28 Pfizer Limited Methods of treating chronic pain
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
KR101519192B1 (ko) * 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
NZ717704A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
TWI685505B (zh) 2011-05-20 2020-02-21 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
PE20161439A1 (es) 2014-03-21 2017-01-26 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
CN113227140A (zh) 2019-01-08 2021-08-06 H.隆德贝克有限公司 使用抗cgrp抗体急性治疗和快速治疗头痛
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5945416A (en) * 1996-03-25 1999-08-31 Eli Lilly And Company Method for treating pain
WO2002087512A2 (en) * 2001-05-02 2002-11-07 Euro-Celtique, S.A. Once-a-day oxycodone formulations
EP1449531A2 (en) * 1994-11-04 2004-08-25 Euro-Celtique Melt-extruded orally administrable opioid formulations
US20040254156A1 (en) * 2003-06-10 2004-12-16 Bertrand Le Bourdonnec Sulfonylamino phenylacetamide derivatives and methods of their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
EP1449531A2 (en) * 1994-11-04 2004-08-25 Euro-Celtique Melt-extruded orally administrable opioid formulations
US5945416A (en) * 1996-03-25 1999-08-31 Eli Lilly And Company Method for treating pain
WO2002087512A2 (en) * 2001-05-02 2002-11-07 Euro-Celtique, S.A. Once-a-day oxycodone formulations
US20040254156A1 (en) * 2003-06-10 2004-12-16 Bertrand Le Bourdonnec Sulfonylamino phenylacetamide derivatives and methods of their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CERVERO FERNANDO ET AL.: "Visceral pain", LANCET (NORTH AMERICAN EDITION), vol. 353, no. 9170, 19 June 1999 (1999-06-19), pages 2145-2148, XP002370469, ISSN: 0099-5355, the whole document *
KALSO E.: "Oxycodone", JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, ELSEVIER, NEW YORK, NY, US, vol. 29, no. 5, May 2005 (2005-05), pages 47-56, XP004903891, ISSN: 0885-3924, page S51, column 1, paragraphs 4,5, page S51, column 2, paragraph 4 *
POYHIA R. ET AL.: "OXYCODONE AND MORPHINE IN POSTOPERATIVE PAIN TREATMENT", PAIN, no. SUPPL. 5, 1990, page S143, XP009062727 & SIXTH WORLD CONGRESS ON PAIN, ADELAIDE, SOUTH AUSTRALIA, AUSTRALIA, APRIL 1-6, 1990. PAIN., ISSN: 0304-3959, abstract *

Also Published As

Publication number Publication date
TWI432196B (zh) 2014-04-01
ES2333901T3 (es) 2010-03-02
ME01066B (me) 2012-10-20
PL1838318T3 (pl) 2010-03-31
TW200637554A (en) 2006-11-01
AT9895U1 (de) 2008-05-15
AP2007004057A0 (en) 2007-08-31
NO20074174L (no) 2007-10-17
DE202006019887U1 (de) 2007-07-26
KR20080106991A (ko) 2008-12-09
EP1838318B1 (en) 2009-10-21
KR20210131450A (ko) 2021-11-02
ZA200705231B (en) 2008-06-25
HK1107933A1 (en) 2008-04-25
CY1109660T1 (el) 2014-08-13
RS51069B (sr) 2010-10-31
AU2006207498A1 (en) 2006-07-27
KR20230170811A (ko) 2023-12-19
AR052880A1 (es) 2007-04-11
BRPI0606247A2 (pt) 2009-06-09
DE602006009899D1 (de) 2009-12-03
KR20190135557A (ko) 2019-12-06
ATE446092T1 (de) 2009-11-15
NZ555852A (en) 2010-01-29
IL184530A (en) 2015-01-29
CA2595043A1 (en) 2006-07-27
US20150190393A1 (en) 2015-07-09
IL184530A0 (en) 2007-10-31
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
WO2006077212A1 (en) 2006-07-27
MY144471A (en) 2011-09-30
CA2595043C (en) 2013-11-19
EA200701541A1 (ru) 2008-02-28
JP2008526927A (ja) 2008-07-24
DK200700207U1 (da) 2007-08-24
SI1838318T1 (sl) 2010-02-26
CN101106996B (zh) 2013-10-23
NO338968B1 (no) 2016-11-07
KR20200128451A (ko) 2020-11-12
AU2006207498B2 (en) 2009-11-19
DK1838318T3 (da) 2010-01-04
US9271974B2 (en) 2016-03-01
KR20140091782A (ko) 2014-07-22
HRP20090679T1 (hr) 2010-01-31
EP1838318A1 (en) 2007-10-03
JP5049139B2 (ja) 2012-10-17
KR20070100368A (ko) 2007-10-10
KR20120089710A (ko) 2012-08-13
DK200700207U3 (da) 2007-09-28
UA85471C2 (ru) 2009-01-26
KR20220165797A (ko) 2022-12-15
US20080200493A1 (en) 2008-08-21
PT1838318E (pt) 2009-12-15
AP2249A (en) 2011-07-18
CN101106996A (zh) 2008-01-16

Similar Documents

Publication Publication Date Title
US9271974B2 (en) Use of oxycodone for treating visceral pain
ES2758831T3 (es) Nuevas y potentes formas de dosificación de tapentadol
MX2010005680A (es) Composiciones de tapentadol.
ES3036967T3 (en) Delayed release deferiprone tablets and methods of using the same
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
CN104884053B (zh) 用于改善记忆表现的益智组合物
CN111328282A (zh) 加波沙朵在治疗发作性睡病中的用途
JP2022540917A (ja) 治療的処置のためのガボキサドール含有医薬製剤
HK1107933B (en) Use of oxycodone for treating visceral pain
RU2797615C2 (ru) Способы применения феноксипропиламинового соединения для лечения боли
HK40031715A (en) Use of gaboxadol in the treatment of narcolepsy

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ KG RU